
Feature|Articles|October 30, 2026
Closing the Pediatric Evidence Gap
Author(s)Martine Dehlinger-Kremer, Ph.D.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Advertisement
Advertisement
Treatment decisions in childhood can have a profound impact on health outcomes later in life. However, clinicians and families often have to make those decisions without evidence generated specifically in children. This uncertainty becomes even greater when the condition is serious, treatment options are limited, and decisions cannot wait.
Related to this article

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.

Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
Advertisement
Advertisement

